+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antimicrobial Resistance Diagnostics Market Size, Share & Trends Analysis Report by Technology (Microbiology Culture, PCR), End-use (Hospitals, Diagnostic Laboratories), Pathogen, Region, and Segment Forecasts, 2025-2030

  • PDF Icon

    Report

  • 120 Pages
  • October 2024
  • Region: Global
  • Grand View Research
  • ID: 5702233
Description Jump to:
The global antimicrobial resistance diagnostics market size is expected to reach USD 6.70 billion by 2030, registering a CAGR of 6.55% from 2025 to 2030. The increased risk of developing drug-resistant bacterial infections, especially in healthcare facilities, and increasing government & non-government bodies’ efforts to combat the threat of AMR are the major factor contributing to market growth. In addition, various strategic initiatives undertaken by leading market players to manage antimicrobial resistance are also contributing to market expansion. For instance, in March 2021, bioMerieux and GIZ collaborated to support the Nigerian center for disease control to strengthen the fight against AMR.

The rising adoption of rapid testing and PoC tests for drug-resistant bacterial infections is anticipated to augment the market over the projected period. Moreover, leading market players such as Danaher, Abbott, and others have a robust product portfolio of rapid diagnostic tests for antimicrobial-resistant infections. Furthermore, the increasing involvement of non-government bodies such as AMR Industry Alliance is assisting regulatory bodies to make strategies to boost the development of diagnostic solutions to manage antimicrobial resistance.

Increasing funding for the development of novel and automated test solutions for the diagnosis of antimicrobial-resistant infections is anticipated to boost market growth over the forecast period. For instance, in May 2022, the European Investment Bank funded more than USD 24 million to POCARED Diagnostics for the R&D of fully automated testing of microbial diseases. POCARED Diagnostics is involved in the development of novel microbiology tests that can provide results within hours.

Antimicrobial resistance is expected to rise in the coming years. Hence, demand for accurate & fast testing options is expected to increase for the effective management and progression monitoring of antimicrobial resistance. According to the CDC, the annual direct healthcare expenditure of antimicrobial resistance is around USD 20 billion in the U.S. High cost of disease management is driving the demand for rapid tests for the diagnosis of infections at an early stage.

Key market players are continuously involved in the development of novel tests to strengthen their market position. Moreover, other strategies such as acquisitions, partnerships, and collaborations are also adopted by leading players to expand their product portfolio in different parts of the globe. For instance, in August 2022, Accelerate Diagnostics and BD announced a collaboration to combat the threat of antimicrobial resistance. As per the deal, BD will provide Accelerate Diagnostics rapid diagnostic solutions for antibiotics-associated resistance to its vast customers.

Antimicrobial Resistance Diagnostics Market Report Highlights

  • The PCR segment dominated the market and accounted for the largest revenue share of 24.19% in 2024. Advancements in PCR technology, along with its widespread adoption due to its high accuracy, are key factors driving the significant share of this segment.
  • In 2024, the methicillin resistant staphylococcus aureus segment held the largest market share at 28.33%. The rising incidence of MRSA in hospital settings is a key driver for the expansion of this segment.
  • In 2024, the hospitals segment led the market, accounting for 48.07% of the revenue share. The growth of this segment is driven by several factors, including the rising incidence of hospital-acquired infections and increased hospitalizations due to antimicrobial-resistant (AMR) infections, which often lead to prolonged hospital stays.
  • North America antimicrobial resistance diagnostics market dominated the overall global market with a revenue share of 42.03% in 2024.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
  • Competitive Landscape: Explore the market presence of key players worldwide
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

The leading players in the Antimicrobial Resistance Diagnostics market include:

  • bioMerieux
  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • Hologic, Inc.
  • BD
  • Danaher
  • Accelerate Diagnostics, Inc.
  • Molsid
  • Vela Diagnostics
  • Visby Medical, Inc.
  • OpGen


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Pathogen
1.2.3. End Use
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Antimicrobial Resistance Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increase in risk of developing drug - resistant bacterial infections
3.2.1.2. Introduction of novel technologies to diagnose AMR infections
3.2.1.3. Favorable government initiatives
3.2.2. Market Restraint Analysis
3.2.2.1. Presence of stringent rules and regulations pertaining to diagnostics
3.3. Antimicrobial Resistance Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Antimicrobial Resistance Diagnostics Market: Technology Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Antimicrobial Resistance Diagnostics Market: Technology Movement Analysis
4.3. Antimicrobial Resistance Diagnostics Market by Technology Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Microbiology Culture
4.5.1. Microbiology Culture Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Immunoassay
4.6.1. Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.2. PCR
4.6.2.1. PCR Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.3. NGS
4.6.3.1. NGS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.4. Mass Spectrometry
4.6.4.1. Mass Spectrometry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.5. Rapid & Point of Care
4.6.5.1. Rapid & Point of Care Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.6. Others
4.6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Antimicrobial Resistance Diagnostics Market: Pathogen Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Antimicrobial Resistance Diagnostics Market: Pathogen Movement Analysis
5.3. Antimicrobial Resistance Diagnostics Market by Pathogen Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Drug Resistant Streptococcus Pneumoniae (DRSP)
5.5.1. Drug Resistant Streptococcus Pneumoniae (DRSP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Drug Resistant Campylobacter (DRC)
5.6.1. Drug Resistant Campylobacter (DRC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Clostridium Difficile (CD)
5.7.1. Clostridium Difficile (CD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Drug Resistant Neisseria Gonorrhoeae (DRNG)
5.8.1. Drug Resistant Neisseria Gonorrhoeae (DRNG) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Drug Resistant Salmonella (DRNTS)
5.9.1. Drug Resistant Salmonella (DRNTS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.10. Others
5.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Antimicrobial Resistance Diagnostics Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Antimicrobial Resistance Diagnostics Market: End Use Movement Analysis
6.3. Antimicrobial Resistance Diagnostics Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Hospitals
6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Diagnostic Laboratories
6.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Pharmaceutical & Biotechnology Companies
6.7.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Others
6.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Antimicrobial Resistance Diagnostics Market: Regional Estimates & Trend Analysis
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Company Market Share Analysis, 2024
8.4. Key Company Profiles
8.4.1. bioMerieux
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. F. Hoffmann - La Roche Ltd
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Abbott
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. BD
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Danaher
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Accelerate Diagnostics, Inc.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Molsid
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Vela Diagnostics
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Visby Medical, Inc.
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Hologic, Inc.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 4 Global Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 5 Global Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 6 North America Antimicrobial Resistance Diagnostics market, by region, 2018 - 2030 (USD Million)
Table 7 North America Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 8 North America Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 9 North America Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 10 U.S Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 11 U.S Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 12 U.S Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 13 Mexico Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 14 Mexico Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 15 Mexico Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 16 Canada Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 17 Canada Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 18 Canada Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 19 Europe Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
Table 20 Europe Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 21 Europe Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 22 Europe Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 23 UK Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 24 UK Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 25 UK Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 26 Germany Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 27 Germany Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 28 Germany Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
Table 29 France Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 30 France Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 31 France Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
Table 32 Italy Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 33 Italy Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 34 Italy Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 35 Spain Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 36 Spain Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 37 Spain Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 38 Denmark Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 39 Denmark Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 40 Denmark Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
Table 41 Norway Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 42 Norway Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 43 Norway Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 44 Sweden Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 45 Sweden Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 46 Sweden Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 50 Asia Pacific Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 51 Japan Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 52 Japan Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 53 Japan Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 54 China Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 55 China Antimicrobial Resistance Diagnostics market, by Pathogen 2018 - 2030 (USD Million)
Table 56 China Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
Table 57 India Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 58 India Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 59 India Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 60 Australia Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 61 Australia Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 62 Australia Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 63 South Korea Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 64 South Korea Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 65 South Korea Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 66 Thailand Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 67 Thailand Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 68 Thailand Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 69 Latin America Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
Table 70 Latin America Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 71 Latin America Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 72 Latin America Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 73 Brazil Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 74 Brazil Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 75 Brazil Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 76 Argentina Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 77 Argentina Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 78 Argentina Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 79 Middle East & Africa Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 83 South Africa Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 84 South Africa Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 85 South Africa Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 89 UAE Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 90 UAE Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 91 UAE Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
Table 92 Kuwait Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
Table 93 Kuwait Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
Table 94 Kuwait Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Information procurement
Fig. 2 Primary research pattern
Fig. 3 Market research approaches
Fig. 4 Value chain-based sizing & forecasting
Fig. 5 Market formulation & validation
Fig. 6 Antimicrobial Resistance Diagnostics market segmentation
Fig. 7 Market driver analysis (current & future impact)
Fig. 8 Market restraint analysis (current & future impact)
Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 10 Porter’s five forces analysis
Fig. 11 Antimicrobial resistance diagnostics market, Technology outlook key takeaways, 2024 & 2030 (USD Million)
Fig. 12 Antimicrobial resistance diagnostics market: Pathogen movement analysis, 2024 & 2030 (USD Million)
Fig. 13 Antimicrobial resistance diagnostics market: end use movement analysis, 2024 & 2030 (USD Million)
Fig. 14 Microbiology Culture market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 15 Immunoassay market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 16 PCR market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 17 NGS market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Mass Spectrometry market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Rapid & Point of Care market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Drug Resistant Streptococcus Pneumoniae market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Drug Resistant Campylobacter market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Clostridium Difficile market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Methicillin Resistant Staphylococcus Aureus market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Drug Resistant Neisseria Gonorrhoeae market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Drug Resistant Salmonella market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Hospitals market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Diagnostic Laboratories market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Pharmaceutical & Biotechnology Companies market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 North America antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 US antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Canada antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Mexico antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Europe antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 UK antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Germany antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 France antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Spain antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Italy antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Norway antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Denmark antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Sweden antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Asia Pacific antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 China antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Japan antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 India antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 South Korea antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Australia antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Thailand antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Latin America antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Brazil antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Argentina antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Middle East and Africa antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 South Africa antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Saudi Arabia antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 UAE antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Kuwait antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 List of key emerging company’s/Allergen disruptors/innovators

Companies Mentioned

  • bioMerieux
  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • Hologic, Inc.
  • BD
  • Danaher
  • Accelerate Diagnostics, Inc.
  • Molsid
  • Vela Diagnostics
  • Visby Medical, Inc.
  • OpGen

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 4.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.7 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antimicrobial Resistance Surveillance Market by Component, End-User - Global Forecast 2025-2030 - Product Image

Antimicrobial Resistance Surveillance Market by Component, End-User - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Antimicrobial Resistance Diagnostic Market by Product Type, Testing Location, Facility Type - Global Forecast 2025-2030 - Product Image

Antimicrobial Resistance Diagnostic Market by Product Type, Testing Location, Facility Type - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Antibiotic Resistance Market Size, Share & Trends Analysis Report by Disease (cUTI, CDI), Pathogen, Drug Class, Mechanism of Action, Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Antibiotic Resistance Market Size, Share & Trends Analysis Report by Disease (cUTI, CDI), Pathogen, Drug Class, Mechanism of Action, Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 120 Pages
  • Global
From
Antimicrobial Resistance Surveillance Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F - Product Image

Antimicrobial Resistance Surveillance Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F

  • Report
  • 182 Pages
  • Global
From
Antimicrobial Resistance Surveillance - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Antimicrobial Resistance Surveillance - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 105 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.